January 2008

Clinical Data, Affymetrix in Marketing Deal

Wednesday, January 30, 2008

Newton, Mass.-based analytical services company Clinical Data signed a service and marketing agreement with Affymetrix, a diagnostic technology company based in Santa Clara, Calif. The agreement allows Clinical Data’s two subsidiaries, Cogenics and Epidauros Biotechnologies AG, to sell Affymetrix’s drug metabolizing enzymes and transporter (DMET) solution. DMET is a method for analyzing the genetics of drug metabolism. It allows sponsors to gain valuable data on pharmacokinetics compared to a patient’s genetic profile.

[Read More]

LabCorp to Acquire Tandem Labs

Monday, January 28, 2008

Burlington, N.C.-based LabCorp has signed an agreement to acquire the bioanalytical services company Tandem Labs for an undisclosed amount. Tandem performs analytical lab work for drugs in all stages of development including discovery, preclinical, and clinical. Founded in 1981 as Northwest Toxicology Consultants, the company initially operated as a clinical toxicology reference laboratory.

[Read More]

Type I Diabetes Drug See Positive Results in Phase II

Thursday, January 24, 2008

Diamyd Medical (formerly issued positive long-term results from a phase IIb trial of Diamyd, GAD-65), recombinant glutamic acid decarboxylase (GAD) delivered with alum for injection, for the treatment of type I diabetes. This randomized study enrolled seventy pediatric and adolescent subjects in Sweden.

[Read More]

Kendle Looking to Grow Phase I Business

Monday, January 21, 2008

Cincinnati-based CRO Kendle is expanding its phase I business with the appointment of Philip Davies, a 20-year industry veteran in early stage research, and made another key hire to grow its Asia-Pacific operations.

[Read More]

Negative or Positive Trial Results?

Thursday, January 17, 2008

There’s some great quotes in the Wall Street Journal’s story about the New England Journal of Medicine’s assertion that effectiveness of antidepressants has been exaggerated by selective publication of positive clinical trial results.

[Read More]